TY - JOUR
T1 - Serum YKL-40 predicts long-term mortality in patients with stable coronary disease
T2 - A prognostic study within the CLARICOR trial
AU - Harutyunyan, Marina
AU - Gøtze, Jens P
AU - Winkel, Per
AU - Johansen, Julia S
AU - Hansen, Jørgen Fischer
AU - Jensen, Gorm Boje
AU - Hilden, Jørgen
AU - Kjøller, Erik
AU - Kolmos, Hans Jørn Jepsen
AU - Gluud, Christian
AU - Kastrup, Jens
N1 - Copyright © 2012 Elsevier GmbH. All rights reserved.
PY - 2013
Y1 - 2013
N2 - OBJECTIVE: We investigated whether the inflammatory biomarker YKL-40 could improve the long-term prediction of death made by common risk factors plus high-sensitivity C-reactive protein (hs-CRP) and N-terminal-pro-B natriuretic peptide (NT-proBNP) in patients with stable coronary artery disease (CAD). BACKGROUND: Non-hospitalized CAD patients are usually followed in general practice. There is a need for identify biomarkers which could help to foresee the prognoses of these patients. Elevated serum YKL-40 is a short-term predictor for myocardial infarction, cardiovascular mortality and all-cause mortality in patients with stable CAD. METHODS: Serum YKL-40, hs-CRP, and NT-proBNP were measured in 4265 (97.6%) of the 4372 patients with stable CAD included in the CLARICOR trial, and death was registered in a 6-years follow-up period. RESULTS: The median serum YKL-40 was 110μg/L [IQR=93], hs-CRP 2.8mg/L [IQR=4.74], and NT-proBNP 203ng/L [IQR=407]. During 6 years follow-up period 923 (21.1%) patients died. After adjustment for type of intervention, risk factors (age, sex, hypertension, diabetes, smoking status, and previous myocardial infarction) and medical treatment (diuretics, digoxin, and statin) serum YKL-40 (transformed as ln(max(82, YKL-40/μg/L)) was significantly associated with all-cause mortality [hazard ratio (HR)=1.55, 95% CI=1.39-1.73, p
AB - OBJECTIVE: We investigated whether the inflammatory biomarker YKL-40 could improve the long-term prediction of death made by common risk factors plus high-sensitivity C-reactive protein (hs-CRP) and N-terminal-pro-B natriuretic peptide (NT-proBNP) in patients with stable coronary artery disease (CAD). BACKGROUND: Non-hospitalized CAD patients are usually followed in general practice. There is a need for identify biomarkers which could help to foresee the prognoses of these patients. Elevated serum YKL-40 is a short-term predictor for myocardial infarction, cardiovascular mortality and all-cause mortality in patients with stable CAD. METHODS: Serum YKL-40, hs-CRP, and NT-proBNP were measured in 4265 (97.6%) of the 4372 patients with stable CAD included in the CLARICOR trial, and death was registered in a 6-years follow-up period. RESULTS: The median serum YKL-40 was 110μg/L [IQR=93], hs-CRP 2.8mg/L [IQR=4.74], and NT-proBNP 203ng/L [IQR=407]. During 6 years follow-up period 923 (21.1%) patients died. After adjustment for type of intervention, risk factors (age, sex, hypertension, diabetes, smoking status, and previous myocardial infarction) and medical treatment (diuretics, digoxin, and statin) serum YKL-40 (transformed as ln(max(82, YKL-40/μg/L)) was significantly associated with all-cause mortality [hazard ratio (HR)=1.55, 95% CI=1.39-1.73, p
U2 - 10.1016/j.imbio.2012.10.015
DO - 10.1016/j.imbio.2012.10.015
M3 - Journal article
C2 - 23294528
SN - 0171-2985
VL - 218
SP - 945
EP - 951
JO - Immunobiology
JF - Immunobiology
IS - 7
ER -